Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Abstract Background There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocyte ratio (NLR) and duration of prior anti-vascular endothelial growth f...

Full description

Bibliographic Details
Main Authors: Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana, Ulka Vaishampayan
Format: Article
Language:English
Published: BMJ Publishing Group 2017-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Biomarkers
Kidney cancer
Predictive
Prognostic marker
Neutrophil lymphocyte ratio
Immune checkpoint inhibitors
Online Access:http://link.springer.com/article/10.1186/s40425-017-0287-5

Internet

http://link.springer.com/article/10.1186/s40425-017-0287-5

Similar Items